Jefferies Financial Group Inc. Makes New Investment in Establishment Labs Holdings Inc. $ESTA

Posted by Francis Steltz on Aug 31st, 2026

Jefferies Financial Group Inc. bought a new position in Establishment Labs Holdings Inc. (NASDAQ:ESTA – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 8,739 shares of the company’s stock, valued at approximately $750,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ESTA. KBC Group NV bought a new position in Establishment Labs in the 1st quarter worth approximately $28,000. Quarry LP bought a new stake in Establishment Labs during the 3rd quarter valued at $34,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Establishment Labs during the second quarter worth $43,000. Kestra Advisory Services LLC purchased a new stake in shares of Establishment Labs during the fourth quarter worth $47,000. Finally, Osaic Holdings Inc. boosted its holdings in shares of Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after acquiring an additional 1,800 shares during the period. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $70.64 on Monday. The stock’s 50-day moving average is $85.00 and its 200 day moving average is $74.94. The company has a market cap of $2.11 billion, a PE ratio of -53.92 and a beta of 1.07. The company has a debt-to-equity ratio of 12.11, a current ratio of 3.84 and a quick ratio of 2.52. Establishment Labs Holdings Inc. has a 1 year low of $36.53 and a 1 year high of $97.59.

Establishment Labs (NASDAQ:ESTA – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The business had revenue of $67.54 million during the quarter, compared to analysts’ expectations of $65.79 million. During the same quarter last year, the business posted ($0.57) EPS. The company’s quarterly revenue was up 31.7% compared to the same quarter last year. Sell-side analysts anticipate that Establishment Labs Holdings Inc. will post -1.15 EPS for the current year.

Analyst Upgrades and Downgrades

ESTA has been the subject of several recent research reports. JPMorgan Chase & Co. lifted their price target on Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Canaccord Genuity Group set a $105.00 price target on shares of Establishment Labs in a report on Thursday, August 6th. Needham & Company LLC raised their price objective on Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 6th. BTIG Research lifted their target price on shares of Establishment Labs from $96.00 to $103.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Citigroup upgraded Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price objective for the company in a research report on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Establishment Labs has a consensus rating of “Moderate Buy” and an average target price of $100.25.

Get Our Latest Stock Analysis on Establishment Labs

About Establishment Labs

(Free Report)

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.